Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 in Sepsis-related Thrombocytopenia
NCT07595133Phase 1Not yet recruiting
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 1, randomised trial of romiplostim in Thrombocytopenia (2 arms), sponsored by Shanghai Tenth People's Hospital. Primary endpoint: Effective rate of platelet-stimulating treatment at 7 days. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT07595133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07595133.